Clinical trial
A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder
NCT05376150 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 19, 2022
- Completion date
- October 16, 2023
- Enrollment
- 168 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.